Source: Annual Congress 2013 –Treatment of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Wenzel, J. Ming, J. Hamilton, A. Radin, R. Rocklin, T. Hultsch, L. Wang, F. Skobieranda, G. Pirozzi (Pittsburgh, Bridgewater, Tarrytown, Cambridge, United States Of America). Therapeutic blockade of IL-4 and 13 signaling with dupilumab (SAR231893/REGN668) inhibits key biomarkers in asthma. Eur Respir J 2013; 42: Suppl. 57, 3539

Member's Comments

No comment yet.

Related content which might interest you: Blockade of TSLP pathway alters asthma biomarkers Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Importance of levels production of Il-4 in the pathogenesis and formation of the phenotype of asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Activation of the β-catenin pathway by Wnt-1 treatment suppress inflammation in the mouse model of allergic airway disease Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Elevated IL-10 level but not cysteinyl leukotrienes (CysLT) release from leukocytes in vitro correlates with good response to treatment with montelukast in asthmatic patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 ADEPT-derived, U-BIOPRED validated asthma clinical clusters with Th2 and non-Th2 phenotypes Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014 TH2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013 LATE-BREAKING ABSTRACT: A novel role for CCR3 in promoting airways hyperreactivity; Role for CCR3-muscarinic M3 receptor heterodimers Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 The homologous IL-17 cytokines A and F differentially regulate allergic asthma in murine models Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Identification of novel pathogenic mechanisms triggered by arginase activation in patients with COPD Source: International Congress 2016 – Airway response to infection Year: 2016 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 The effect of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Aquaporin-3 potentiates murine asthma through mediating T-cell trafficking and chemokine production Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 IL-25 receptor expression on basophil membrane is related to phenotype and severity of asthma Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Preventative administration of IL-27 improves airway inflammation of ovalbumin –induced asthma mice model via both STAT1 and GADD45γ/p38MAPK pathways Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Systemic cytokine signaling via IL-17 and its relation to clinical characteristics in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: lung function and biomarkers Year: 2015 ARRY-502, a potent, selective, oral CRTh2 antagonist reduces Th2 mediators in patients with mild to moderate Th2-driven asthma Source: International Congress 2014 – Novel approaches to human studies in allergy and asthma Year: 2014